Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Research Report 2024

Publication ID:

PB505248651

Publication Date:

May 6, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

SGLT2 is a member of the sodium-glucose cotransporter family which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney.The growing global type-2 diabetes population promotes the growth of SGLT2 drugs.
The global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors include Eli Lilly, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb and Kotobuki Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors.
Report Scope
The Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Eli Lilly
Janssen Pharmaceuticals
Astellas
Boehringer Ingelheim
AstraZeneca
Bristol Myers Squibb
Kotobuki Pharmaceutical
Segment by Type
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Segment by Application
Hospital
Medical Research Institute
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Overview
1.1 Product Overview and Scope of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors
1.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Segment by Type
1.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Invokana (Canagliflozin)
1.2.3 Jardiance (Empagliflozin)
1.2.4 Farxiga/Forxiga (Dapagliflozin)
1.2.5 Suglat (Ipragliflozin)
1.3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Segment by Application
1.3.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Medical Research Institute
1.3.4 Other
1.4 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 2019-2030
1.4.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 2019-2030
1.4.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Competition by Manufacturers
2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Average Price by Manufacturers (2019-2024)
2.4 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, Product Type & Application
2.7 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Competitive Situation and Trends
2.7.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Players 麻豆原创 Share by Revenue
2.7.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Retrospective 麻豆原创 Scenario by Region
3.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region: 2019-2030
3.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region: 2019-2024
3.2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region: 2025-2030
3.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Region: 2019-2030
3.3.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Region: 2019-2024
3.3.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Region: 2025-2030
3.4 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Facts & Figures by Country
3.4.1 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2019-2030)
3.4.3 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Facts & Figures by Country
3.5.1 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2019-2030)
3.5.3 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2019-2030)
3.6.3 Asia Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2019-2030)
3.7.3 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2019-2030)
3.8.3 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type (2019-2030)
4.1.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type (2019-2024)
4.1.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type (2025-2030)
4.1.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Type (2019-2030)
4.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Type (2019-2024)
4.2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Type (2025-2030)
4.2.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Price by Type (2019-2030)
5 Segment by Application
5.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2019-2030)
5.1.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2019-2024)
5.1.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2025-2030)
5.1.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Application (2019-2030)
5.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Application (2019-2024)
5.2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Application (2025-2030)
5.2.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Eli Lilly Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 Janssen Pharmaceuticals
6.2.1 Janssen Pharmaceuticals Corporation Information
6.2.2 Janssen Pharmaceuticals Description and Business Overview
6.2.3 Janssen Pharmaceuticals Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Janssen Pharmaceuticals Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio
6.2.5 Janssen Pharmaceuticals Recent Developments/Updates
6.3 Astellas
6.3.1 Astellas Corporation Information
6.3.2 Astellas Description and Business Overview
6.3.3 Astellas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Astellas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio
6.3.5 Astellas Recent Developments/Updates
6.4 Boehringer Ingelheim
6.4.1 Boehringer Ingelheim Corporation Information
6.4.2 Boehringer Ingelheim Description and Business Overview
6.4.3 Boehringer Ingelheim Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Boehringer Ingelheim Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio
6.4.5 Boehringer Ingelheim Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Corporation Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.5.4 AstraZeneca Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Bristol Myers Squibb
6.6.1 Bristol Myers Squibb Corporation Information
6.6.2 Bristol Myers Squibb Description and Business Overview
6.6.3 Bristol Myers Squibb Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bristol Myers Squibb Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio
6.6.5 Bristol Myers Squibb Recent Developments/Updates
6.7 Kotobuki Pharmaceutical
6.6.1 Kotobuki Pharmaceutical Corporation Information
6.6.2 Kotobuki Pharmaceutical Description and Business Overview
6.6.3 Kotobuki Pharmaceutical Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kotobuki Pharmaceutical Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio
6.7.5 Kotobuki Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Industry Chain Analysis
7.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Production Mode & Process
7.4 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales and 麻豆原创ing
7.4.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Channels
7.4.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Distributors
7.5 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Customers
8 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Dynamics
8.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Industry Trends
8.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Drivers
8.3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Challenges
8.4 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Eli Lilly
Janssen Pharmaceuticals
Astellas
Boehringer Ingelheim
AstraZeneca
Bristol Myers Squibb
Kotobuki Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.